SAN DIEGO, March 23, 2016 /PRNewswire/ -- Sequenom, Inc.,
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that its wholly owned subsidiary,
Sequenom Laboratories™, has entered into agreements with Anthem
Blue Cross and Blue Shield Health Plans for the states of
Connecticut, Maine, and New
Hampshire, effective March 28,
2016.
The agreements provide in-network coverage for Sequenom
Laboratories noninvasive prenatal tests (NIPT) for both high and
average-risk pregnancies to Anthem's members in those states.
"Our commitment to women's health means doing all we can to
ensure affordable access to our testing services. In keeping
with this commitment, we continue to gain in-network status with
the nation's leading health plans and are encouraged by increasing
payor support of NIPT for average-risk pregnancies," said
Dirk van den Boom, Ph.D., President
and CEO of Sequenom.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing
company dedicated to women's health through the development of
innovative products and services. The Company serves patients
and physicians by providing early patient management
information. For more information, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, HerediT® UNIVERSAL,
MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene® and
VisibiliT™, these molecular genetic laboratory-developed tests
provide early patient management information for obstetricians,
geneticists, and maternal fetal medicine specialists.
Sequenom Laboratories is changing the landscape in genetic
diagnostics using proprietary cutting edge technologies. Visit
www.laboratories.sequenom.com and follow @SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT®, NextView®, SensiGene®,
VisibiliT™ and Sequenom Laboratories™ are
trademarks of Sequenom, Inc. All other trademarks and service marks
are the property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 including statements regarding the development of
innovative products and services, actions to ensure affordable
access to our testing services, continuing to gain in-network
status with the nation's leading health plans and increasing payor
support of NIPT for average-risk pregnancies. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Risks are described more fully
in the Company's filings with the Securities and
Exchange Commission, including without limitation the Company's
most recent Annual Report on Form 10-K and other documents
subsequently filed with or furnished to the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. The Company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Logo - http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-announces-in-network-contracts-with-anthem-blue-cross-and-blue-shield-plans-for-connecticut-maine-and-new-hampshire-300240101.html
SOURCE Sequenom, Inc.